Avalo Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Avalo Therapeutics, Inc. on September 11, 2023. The filing discloses the entry into a Material Definitive Agreement regarding the divestiture of specific assets.
Key Financial Metrics and Transaction Details
The Company entered into an Asset Purchase Agreement with AUG Therapeutics, LLC to sell rights to the "800 Series" assets (AVTX-801, AVTX-802, and AVTX-803). The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for the reporting period.
- Upfront Payment: $150,000
- Contingent Milestone Payments: $15,000,000 per compound upon first FDA approval for a non-Rare Pediatric Disease indication (Potential aggregate: $45,000,000).
- Priority Review Voucher: Up to 20% of payments granted to AUG upon sale of any priority review voucher, net of selling costs.
- Liabilities Assumed: AUG will assume up to $150,000 of certain pre-existing liabilities and all costs relating to the 800 Series from the agreement date.
Material Changes and Transaction Status
The primary material change is the agreement to divest the 800 Series assets. The transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions, including obtaining third-party consents. The agreement includes a termination right for either party if the closing is not consummated within 60 days of the agreement date.
Outlook, Risks, and Management Commentary
Avalo and AUG have entered into a Transition Services Agreement for short-term assistance regarding the asset transfer. The agreement includes customary indemnification provisions where Avalo indemnifies AUG for losses resulting from breaches of representations or warranties. Investors are cautioned not to rely on representations and warranties as characterizations of the actual state of facts, as these were made solely for the benefit of the parties as of the agreement date.
Key Facts for Investor Verification
- Verify the closing status of the transaction in the fourth quarter of 2023.
- Confirm the receipt of the $150,000 upfront payment upon closing.
- Monitor the development progress of the 800 Series assets by AUG to assess the likelihood of triggering the $45 million in milestone payments.
- Review the specific terms of the Transition Services Agreement for potential ongoing costs or obligations.
- Check for any updates regarding the assumption of the $150,000 in liabilities by AUG.